Active Recombinant Human BACE1 protein(Met1-Thr457), hFc-tagged

• Cat.No.: BACE1-253H
• Product Overview: Recombinant Human BACE1 protein(NP_036236.1)(Met1-Thr457), fused with C-terminal hFc tag, was expressed in HEK293.

Specification

• similar: BACE1
• Alias: BACE1; beta-site APP-cleaving enzyme 1; BACE, beta site APP cleaving enzyme; beta-secretase 1; asp 2; memapsin-2; APP beta-secretase; aspartyl protease 2; beta-site APP cleaving enzyme 1; beta-secretase 1 precursor variant 1; transmembrane aspartic proteinase Asp2; membrane-associated aspartic protease 2; beta-site amyloid beta A4 precursor protein-cleaving enzyme; ASP2; BACE; HSPC104; FLJ90568; KIAA1149
• Source: HEK293
• Species: Human
• Conjugate: C-hFc
• Tag: Fc
• Protein length: Met1-Thr457
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Bioactivity: Measured by its ability to cleave a fluorogenic peptide substrate, Mca-SEVNLDAEFRK(Dpn)RR-NH2. The specific activity is >0.5 pmoles/min/μg.
• MolecularMass: The recombinant human BACE1/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 674 amino acids and has a calculated molecular mass of 75 kDa. As a result of glycosylation, the rhBACE1/Fc monomer migrates as an approximately 100-105 kDa protein in SDS-PAGE under reducing conditions.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: > 90 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.
• GeneName: BACE1 beta-site APP-cleaving enzyme 1 [ Homo sapiens ]
• GeneNameWeblink: 23621
• OfficialSymbol: BACE1
• OfficialSymbolWeblink: 23621
• GeneIDWeblink: 23621
• mRNARefseq: NM_001207048
• mRNARefseqWeblink: NM_001207048.1
• ProteinRefseqWeblink: NP_001193977.1
• MIMWeblink: 604252
• UniProtID: P56817
• UniProtIDWeblink: P56817
• Synonyms: BACE1; beta-site APP-cleaving enzyme 1; BACE, beta site APP cleaving enzyme; beta-secretase 1; asp 2; memapsin-2; APP beta-secretase; aspartyl protease 2; beta-site APP cleaving enzyme 1; beta-secretase 1 precursor variant 1; transmembrane aspartic proteinase Asp2; membrane-associated aspartic protease 2; beta-site amyloid beta A4 precursor protein-cleaving enzyme; ASP2; BACE; HSPC104; FLJ90568; KIAA1149
• Gene ID: 23621
• MIM: 604252

Gene Information

• Synonyms: BACE1; beta-site APP-cleaving enzyme 1; BACE, beta site APP cleaving enzyme; beta-secretase 1; asp 2; memapsin-2; APP beta-secretase; aspartyl protease 2; beta-site APP cleaving enzyme 1; beta-secretase 1 precursor variant 1; transmembrane aspartic proteinase Asp2; membrane-associated aspartic protease 2; beta-site amyloid beta A4 precursor protein-cleaving enzyme; ASP2; BACE; HSPC104; FLJ90568; KIAA1149
• Gene ID: 23621
• MIM: 604252

Reviews

07/27/2020

Such support ensures researchers have access to reliable tools and expertise, facilitating their investigations into the functions, mechanisms, and disease relevance of BACE1 protein.

12/23/2019

A manufacturer can serve as a collaborative partner, engaging in discussions, and exchanging knowledge with researchers.

09/30/2019

Using BACE1 protein in trials provides advantages such as its involvement in cellular processes and its disease associations.

Q&As

Are there any potential side effects associated with BACE1 inhibition?

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

How is BACE1 linked to Alzheimer's disease?

BACE1 is implicated in Alzheimer's disease as it initiates the cleavage of APP, leading to the formation of beta-amyloid plaques, a hallmark of the disease.

How can BACE1 inhibitors potentially benefit Alzheimer's patients?

BACE1 inhibitors may slow down or prevent the accumulation of beta-amyloid plaques, potentially delaying the progression of Alzheimer's disease.

Are there any ongoing clinical trials involving BACE1 inhibitors?

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

Are there clinical applications of BACE1 inhibitors?

Yes, BACE1 inhibitors are being explored as potential therapeutic agents for Alzheimer's disease to reduce the production of beta-amyloid peptides.